| 杨杨，毛更生，宋玥娇，田荣，聂庆彬，孙剑.重组人促红细胞生成素联合预见性双侧去骨瓣
减压术对重型颅脑损伤的疗效[J].神经损伤功能重建,2019,14(6):278-280 |
| 重组人促红细胞生成素联合预见性双侧去骨瓣
减压术对重型颅脑损伤的疗效 |
| Effects of Recombinant Human Erythropoietin Combined with Predictive Bilateral DecompressiveCraniectomy in Patients with Severe Craniocerebral Injury |
| |
| DOI： |
| 中文关键词: 重型颅脑损伤 重组人促红细胞生成素 预见性双侧去骨瓣减压术 预后 神经功能 |
| 英文关键词: severe craniocerebral injury recombinant human erythropoietin predictive bilateral decompressive
craniectomy prognosis nerve function |
| 基金项目: |
|
| 摘要点击次数: 2650 |
| 全文下载次数: 2847 |
| 中文摘要: |
| 目的：探讨重组人促红细胞生成素联合预见性双侧去骨瓣减压术治疗重型颅脑损伤的疗效。方法：
重型颅脑损伤患者98 例随机分为观察组和对照组，各49 例。在基础治疗的基础上，对照组采取预见性双侧
去骨瓣减压术治疗，观察组采取重组人促红细胞生成素联合预见性双侧去骨瓣减压术治疗。比较治疗前、
后，2 组血清S-100β蛋白、NSE水平，美国国立卫生研究院卒中量表（NIHSS）评分，格拉斯哥昏迷量表（GCS）
评分及随访6 个月后的格拉斯哥预后量表（GOS）评分。结果：治疗后2 组NIHSS 评分均较治疗前降低，且
观察组较对照组低，GCS评分均较治疗前提高，且观察组较对照组高（均P＜0.05）；2 组血清S-100β蛋白、
NSE水平均较治疗前降低，且观察组较对照组低（均P＜0.05）；治疗后随访6 个月，观察组GOS评分为5 分
和4 分的患者多于对照组（P＜0.05）。结论：采用重组人促红细胞生成素联合预见性双侧去骨瓣减压术治疗
重型颅脑损伤患者能显著降低患者神经功能损伤及昏迷程度，改善患者预后。 |
| 英文摘要: |
| To investigate the therapeutic effect of recombinant human erythropoietin combined
with predictive bilateral decompressive craniectomy in patients with severe craniocerebral injury. Methods: In
this study, 98 patients with severe craniocerebral injury were randomly divided into the observation group and
control group with 49 patients per group. On top of basic treatment, the control group was treated with predictive
bilateral decompressive craniectomy and the observation group with recombinant human erythropoietin
combined with predictive bilateral decompressive craniectomy. The expression level of related indexes of serum
nerve injury [S-100β protein and neuron specific enolase (NSE)] and degree of neurological impairment (NIHSS
score) and coma (GCS score) before and after treatment were compared between the two groups. After 6 months,
the prognosis (GOS) of the two groups was compared. Results: NIHSS scores of the two groups after treatment
were lower than those before treatment, and scores of the observation group were lower than those of the control
group. After treatment, GCS scores of both groups were higher than those before treatment with the observation
group showing higher scores than the control group (P＜0.05). After treatment, the serum levels of S-100 β
protein and NSE of the two groups were lower than those before treatment, and levels in the observation group
were lower than those in the control group (all P＜0.05). Six months after treatment, the number of patients in
the observation group with a GOS of 5 or 4 was greater than that in the control group (P＜0.05). Conclusion:
Recombinant human erythropoietin combined with predictive bilateral decompressive craniectomy in the
treatment of patients with severe craniocerebral injury can significantly reduce the degree of neurological
impairment and coma in patients and improve their prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |